Future prospects and therapeutic potential of streptogramins

Keyphrases

• Antibacterial Agents 33%
• Antibiotics 33%
• Bacterial Infection 33%
• Clinical Trials 33%
• Endocarditis 33%
• Enterococcus 66%
• Enterococcus Faecium 33%
• Epidemiological Trends 33%
• Epidemiology 33%
• Foreign Body 66%
• Gram-positive Bacteria 33%
• Gram-positive Cocci 33%
• Gram-positive Pathogens 33%
• Indwelling Medical Devices 33%
• Infection Rate 33%
• Infection Treatment 33%
• Lactams 33%
• Lincosamides 33%
• Macrolides 66%
• Methicillin 33%
• Methicillin-resistant Coagulase-negative Staphylococci 33%
• Multiresistant 66%
• New Antibacterials 33%
• Osteomyelitis 33%
• Penicillin 33%
• Semi-synthetic 33%
• Sepsis 33%
• Skin Tissue 33%
• Soft Tissue Infection 33%
• Staphylococcal Infections 33%
• Staphylococcus Aureus 33%
• Streptococcus Pneumoniae 33%
• Streptogramins 100%
• Susceptibility Pattern 33%
• Teicoplanin 33%
• Therapeutic Potential 100%
• Tolerability 33%
• Vancomycin 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotics 20%
• Antiinfective Agent 40%
• Bacterial Infection 20%
• Clinical Trial 20%
• Coagulase Negative Staphylococcus 20%
• Endocarditis 20%
• Enterococcus 40%
• Enterococcus faecium 20%
• Foreign Body 40%
• Gram Positive Bacterium 20%
• Gram Positive Cocci 20%
• Infection 100%
• Infectious Agent 20%
• Lactam 20%
• Lincosamide 20%
• Macrolide 40%
• Methicillin-Resistant Staphylococcus Aureus 40%
• Meticillin 40%
• Osteomyelitis 20%
• Penicillin Derivative 20%
• Sepsis 20%
• Soft Tissue Infection 20%
• Staphylococcal Infection 20%
• Staphylococcus Aureus 20%
• Streptococcus 40%
• Streptogramin Derivative 100%
• Teicoplanin 20%
• Tolerability 20%
• Vancomycin 60%